186 related articles for article (PubMed ID: 10418960)
21. Development of drug resistance is reduced with idarubicin relative to other anthracyclines.
Hargrave RM; Davey MW; Davey RA; Kidman AD
Anticancer Drugs; 1995 Jun; 6(3):432-7. PubMed ID: 7670142
[TBL] [Abstract][Full Text] [Related]
22. The absence of stereoselective P-glycoprotein- and multidrug resistance-associated protein-mediated transport of daunorubicin.
Loetchutinat C; Heywang C; Priebe W; Garnier-Suillerot A
Biochem Pharmacol; 2001 Sep; 62(5):561-7. PubMed ID: 11585053
[TBL] [Abstract][Full Text] [Related]
23. Flow cytometric study of idarubicin and daunorubicin accumulation and the effect of verapamil in leukemic cell lines and fresh cells from patients with acute non-lymphoblastic leukemia.
Boiron JM; Belloc F; Montastruc M; Cony-Makhoul P; Dumain P; Marit G; Mahon FX; Puntous M; Lopez F; Lacombe F
Leuk Res; 1994 May; 18(5):313-8. PubMed ID: 8182921
[TBL] [Abstract][Full Text] [Related]
24. A new anthracycline with potent anti-leukemic activity overcomes P-glycoprotein multidrug resistance.
Andrivon W; Monneret C; Nafziger J; Florent JC; Guillosson JJ
Leuk Res; 1998 Aug; 22(8):719-25. PubMed ID: 9680099
[TBL] [Abstract][Full Text] [Related]
25. Effect of anthracycline analogs on photolabelling of p-glycoprotein by [125I]iodomycin and [3H]azidopine: relation to lipophilicity and inhibition of daunorubicin transport in multidrug resistant cells.
Friche E; Demant EJ; Sehested M; Nissen NI
Br J Cancer; 1993 Feb; 67(2):226-31. PubMed ID: 8094288
[TBL] [Abstract][Full Text] [Related]
26. The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines.
Consoli U; Priebe W; Ling YH; Mahadevia R; Griffin M; Zhao S; Perez-Soler R; Andreeff M
Blood; 1996 Jul; 88(2):633-44. PubMed ID: 8695811
[TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein inhibitors modulate accumulation and efflux of xenobiotics in extra and intracellular Toxoplasma gondii.
Sauvage V; Aubert D; Bonhomme A; Pinon JM; Millot JM
Mol Biochem Parasitol; 2004 Mar; 134(1):89-95. PubMed ID: 14747146
[TBL] [Abstract][Full Text] [Related]
28. Doxorubicin-peptide conjugates overcome multidrug resistance.
Mazel M; Clair P; Rousselle C; Vidal P; Scherrmann JM; Mathieu D; Temsamani J
Anticancer Drugs; 2001 Feb; 12(2):107-16. PubMed ID: 11261883
[TBL] [Abstract][Full Text] [Related]
29. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.
Wang Y; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Anticancer Drugs; 1999 Nov; 10(10):921-8. PubMed ID: 10630360
[TBL] [Abstract][Full Text] [Related]
30. Pirarubicin nuclear uptake does not correlate with its induced cell death effect during reversal of multidrug resistance by quinine in human K562 and CEM leukemic cells.
Morjani H; Belhoussine R; Lahlil R; Manfait M
Eur J Haematol; 1998 Oct; 61(4):240-9. PubMed ID: 9820630
[TBL] [Abstract][Full Text] [Related]
31. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
[TBL] [Abstract][Full Text] [Related]
32. Comparative evaluation of the intracellular accumulation and DNA binding of idarubicin and daunorubicin in sensitive and multidrug-resistant human leukaemia K562 cells.
Bogush T; Robert J
Anticancer Res; 1996; 16(1):365-8. PubMed ID: 8615637
[TBL] [Abstract][Full Text] [Related]
33. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
Toffoli G; Simone F; Gigante M; Boiocchi M
Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
[TBL] [Abstract][Full Text] [Related]
35. P-glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine.
Frézard F; Pereira-Maia E; Quidu P; Priebe W; Garnier-Suillerot A
Eur J Biochem; 2001 Mar; 268(6):1561-7. PubMed ID: 11248673
[TBL] [Abstract][Full Text] [Related]
36. Intracellular P-gp contributes to functional drug efflux and resistance in acute myeloid leukaemia.
Ferrao P; Sincock P; Cole S; Ashman L
Leuk Res; 2001 May; 25(5):395-405. PubMed ID: 11301107
[TBL] [Abstract][Full Text] [Related]
37. The efflux of anthracyclines in multidrug-resistant cell lines.
Coley HM; Twentyman PR; Workman P
Biochem Pharmacol; 1993 Oct; 46(8):1317-26. PubMed ID: 7902089
[TBL] [Abstract][Full Text] [Related]
38. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
39. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein.
Nielsen D; Maare C; Skovsgaard T
Biochem Pharmacol; 1994 Jun; 47(12):2125-35. PubMed ID: 7913318
[TBL] [Abstract][Full Text] [Related]
40. Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Fukushima T; Inoue H; Takemura H; Kishi S; Yamauchi T; Inai K; Nakayama T; Imamura S; Urasaki Y; Nakamura T; Ueda T
Leuk Res; 1998 Jul; 22(7):625-9. PubMed ID: 9680113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]